Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Linda Kachuri, PhD MPH, Zhaohui Du, M.S., Niels Weinhold, PhD, Gregory Song, Kristin Alyse Rand, PhD MPH, David Van Den Berg, PhD, Amie Hwang, PhD MPH, Xin Sheng, MS, Victor Hom, M.S., Sikander Ailawadhi, MD, Ajay K Nooka, MDMPH, Seema Singhal, MD, Edward S. Peters, DMD, SM, SM, ScD, Cathryn Bock, PhD, Ann Mohrbacher, MD, Alexander Stram, M.S., Sonja I Berndt, PhD, William J. Blot, PhD, Esther M. John, Leslie Bernstein, PhD, M.S., Antoinette Stroup, PhD, Maurizio Zangari, MD, Frits van Rhee, MD PhD, Andrew Olshan, Wei Zheng, MD PhD, Sue Ann Ingles, PhD, Michael Press, PhDMD, John David Carpten, PhD, Stephen J Chanock, MD, Jayesh Mehta, MD, Graham A Colditz, MD DrPH, Jeffrey Wolf, Thomas G. Martin, III, MD, Mark A. Fiala, BS, Howard R. Terebelo, DO, Nalini Janakiraman, MD, Laurence Kolonel, MD, PhD, Kenneth C. Anderson, MD, Loic Le Marchand, MD, PhD, Daniel Auclair, Brian C.-H. Chiu, PhD, Daniel Stram, PhD, Ravi Vij, MBBS, Leon Bernal-Mizrachi, MD, Gareth Morgan, MD PhD, Jeffrey A. Zonder, Carol Ann Huff, MD, Sagar Lonial, Robert Z. Orlowski, MD, PhD, David Conti, PhD, Christopher A. Haiman, PhD, Elad Ziv, MD, John S Witte, PhD, Wendy Cozen, DO,MPH

Blood (2019) 134 (Supplement_1): 4379.

https://doi.org/10.1182/blood-2019-129298

Published: 2019

Journal Articles

Lymphopenia As an Early Predictor of Immune Related Adverse Events

Amir Kamran, MD, Zach Otaibi, DO, Rupin Arun Shah, MBBS, Gene Finley, MD

Blood (2018) 132 (Supplement 1): 4958.

https://doi.org/10.1182/blood-2018-99-119918

Published: 2018

Journal Articles

Comprehensive Population-Based Genetic Fine Mapping and Single-Cell Epigenomics Provide Insights into the Regulation of Human Hematopoiesis

Erik L. Bao, BS, Jacob C. Ulirsch, BS, Caleb A. Lareau, MA, Michael H. Guo, PhD, Rany M. Salem, PhD, Christian Benner, MS, Joel N. Hirschhorn, PhD, Martin J. Aryee, PhD, William J. Greenleaf, PhD, Jason D. Buenrostro, PhD, Vijay G. Sankaran, MD

Blood (2017) 130 (Supplement 1): 2429.

https://doi.org/10.1182/blood.V130.Suppl_1.2429.2429

Published: 2017

Journal Articles

Analysis of the Hematopoietic System in Long-Term Survivors of Allogeneic Stem Cell Transplantation and Their Respective Donors

C. Matthias Wilk, MD, Steffen Boettcher, MD, Fabian Beier, MD, Tim H. Brümmendorf, MD, Markus G Manz, MD

Blood (2017) 130 (Supplement 1): 1996.

https://doi.org/10.1182/blood.V130.Suppl_1.1996.1996

Published: 2017

Journal Articles

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

Parsa Hodjat, MD, Kankana Ghosh, B. Pharm, Priyanka Priyanka, MPH, Beenu Thakral, MBBS,MD, Keyur P. Patel, MD PhD, Mark Routbort, MD PhD, Rashmi Kanagal-Shamana, MD, C. Cameron Yin, MDPhD, Zhuang Zuo, MD PhD, Raja Luthra, PhD, Tariq Muzzafar, MD

Blood (2015) 126 (23): 1392.

https://doi.org/10.1182/blood.V126.23.1392.1392

Published: 2015

Journal Articles

EUTOS Score Predicts Long-Term Outcome in Chronic Myeloid Leukemia Patients Transitioning from Pre-Imatinib Era to Imatinib upon Availability

Pratik Deb, MBBS, Uttam Nath, M.B.B.S., MD, D.M., Rajarshi Aich, M.B.B.S, Siddhartha Sankar Ray, M.B.B.S., MD, D.M., Prantar Chakrabarti, MBBS,MDDM

Blood (2015) 126 (23): 4023.

https://doi.org/10.1182/blood.V126.23.4023.4023

Published: 2015

Journal Articles

Achieving Complete Cytogenetic Response and BCR-ABL PCR IS <1% within 12 Moths Are Important Goals for Imatinib Therapy in Newly Diagnosed, TKI-Naive Chronic Myeloid Leukemia Accelated Phase Patients

Hawk Kim, Eun-Jung Jang, Sung-Eun Lee, Won Sik Lee, MD PhD, Sukjoong Oh, MD PhD, Dong-Wook Kim, MD PhD

Blood (2014) 124 (21): 3158.

https://doi.org/10.1182/blood.V124.21.3158.3158

Published: 2014

Journal Articles

The Transcription Factor IRF8 is a Key Transcription Factor for Basophil Development

Daisuke Kurotaki, PhD, Haruka Sasaki, Naoki Osato, PhD, Izumi Sasaki, PhD, Chika Kaneda, Hideaki Sato, Akira Nishiyama, PhD, Tsuneyasu Kaisho, MD, PhD, Hiroyuki Aburatani, M.D., Ph.D., Herbert C. Morse, III, MD, Keiko Ozato, PhD, Tomohiko Tamura, MD, PhD

Blood (2013) 122 (21): 1197.

https://doi.org/10.1182/blood.V122.21.1197.1197

Published: 2013

Journal Articles

Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy

Noortje Thielen, MD, Johan Richter, MD, PhD, Gisela Barbany, MD PhD, Thoas Fioretos, MD PhD, Frank Giles, MD MB, Bjorn T Gjertsen, MD PhD, Andreas Hochhaus, MD, Gert J. Ossenkoppele, MD PhD, Kimmo Porkka, MD, PhD, Gerrit Jan Schuurhuis, PhD, Sieghart Sopper, PhD, Leif Stenke, MD, PhD, Sara Thunberg, PhD, Dominik Wolf, MD, Jeroen Janssen, MD PhD, Satu Mustjoki, MD, PhD

Blood (2013) 122 (21): 649.

https://doi.org/10.1182/blood.V122.21.649.649

Published: 2013

Journal Articles

Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.

Wolfgang R. Sperr, M.D., Thomas Pfeiffer, Michael Kundi, MD, Christian Sillaber, MD, Susanne Herndlhofer, Peter Valent, MD

Blood (2012) 120 (21): 2783.

https://doi.org/10.1182/blood.V120.21.2783.2783

Published: 2012

Journal Articles

Comparison of Sokal, Hasford and EUTOS Scores in Terms of Long-Term Treatment Outcome According to the Risks in Each Prognostic Model: A Single Center Data Analyzed in 255 Early Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib Mesylate.

Seung-Ah Yahng, Eun-Jung Jang, Soo Young Choi, Yun-Jung Oh, Ju-Hee Bang, Jin-Eok Park, Hye-Lim Jeon, Sung-Eun Lee, Soo-Hyun Kim, Ji-Young Byun, Dong-Wook Kim

Blood (2012) 120 (21): 2794.

https://doi.org/10.1182/blood.V120.21.2794.2794

Published: 2012

Journal Articles

Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364).

Blood (2012) 120 (21): 2840.

https://doi.org/10.1182/blood.V120.21.2840.2840

Published: 2012

Journal Articles

Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors: Is Sokal Score Still a Valid Predictor of Prognosis?

Shivi Jain, MD, Kireet Agrawal, M.D, Abhijai Singh, M.D, Shinoj Pattali, MD, Augustin Haidau, MD, Paula Kovarik, MD, Rose Catchatourian, MD

Blood (2012) 120 (21): 4422.

https://doi.org/10.1182/blood.V120.21.4422.4422

Published: 2012

Journal Articles

Chronic Myeloid Leukemia Presenting with Isolated Thrombocythemia: A Case Revealing Its Stem Cell Biology

Peter Buur van Kooten Niekerk, MD, Anne Stidsholt Roug, MD, PhD, Line Nederby, MSc, PhD, Charlotte Christie Petersen, MSc, Hans Beier Ommen, MD, PhD, Eigil Kjeldsen, MD, Knud Bendix, Charlotte Guldborg Nyvold, MSc, PhD, Peter Hokland, MD, DMSC

Blood (2012) 120 (21): 4427.

https://doi.org/10.1182/blood.V120.21.4427.4427

Published: 2012

Journal Articles

Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials

Kebede Begna, MD, Animesh Pardanani, MBBS, PhD, Ruben A. Mesa, MD, William J Hogan, MBBCh, Mark R. Litzow, MD, Ayalew Tefferi, MD

Blood (2011) 118 (21): 1759.

https://doi.org/10.1182/blood.V118.21.1759.1759

Published: 2011

Journal Articles

Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome

Alice Norton, MB, Georgina Hall, BSc, PhD, MBBS, FRCP, FRCPath, Helen Richmond, RN, Anindita Roy, MB, Gillian Cowan, PhD, Kate Alford, PhD, Keelin O'Donoghue, MB, PhD, Oliver Tunstall, MB, PhD, Aristeidis Chaidos, MD, PhD, Anastasios Karadimitris, MD, PhD, Paresh Vyas, MB, PhD, Irene Roberts, MD

Blood (2010) 116 (21): 876.

https://doi.org/10.1182/blood.V116.21.876.876

Published: 2010

Journal Articles

Role of Focal Adhesion Kinase in Myelotoxicity, Inflammatory Stress Response and Myeloid Cell Functions.

Sasidhar Vemula, Ph.D, Baskar Ramdas, Ph.D., Philip Hanneman, Hillary Beggs, Reuben Kapur, PhD

Blood (2009) 114 (22): 3615.

https://doi.org/10.1182/blood.V114.22.3615.3615

Published: 2009

Journal Articles

Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.

Chad P. Soupir, MD, Jo-Anne Vergilio, MD, Paola Dal Cin, PhD, Alona Muzikansky, MS, Hagop M. Kantarjian, MD, Dan Jones, MD, PhD, Robert P. Hasserjian, MD

Blood (2005) 106 (11): 3290.

https://doi.org/10.1182/blood.V106.11.3290.3290

Published: 2005

Journal Articles

Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.

Hermine Agis, md, Maria T. Krauth, md, Leonhard Muellauer, md, Lawrence B. Schwartz, md, Hans P. Horny, md, Peter Valent, md

Blood (2004) 104 (11): 4754.

https://doi.org/10.1182/blood.V104.11.4754.4754

Published: 2004

NARROW

Comprehensive Investigation of White Blood Cell and Gene Expression Profiles As Risk Factors for Multiple Myeloma in African Americans

Lymphopenia As an Early Predictor of Immune Related Adverse Events

Comprehensive Population-Based Genetic Fine Mapping and Single-Cell Epigenomics Provide Insights into the Regulation of Human Hematopoiesis

Analysis of the Hematopoietic System in Long-Term Survivors of Allogeneic Stem Cell Transplantation and Their Respective Donors

Mutation Analysis in 276 Cases of Newly Diagnosed Acute Myeloid Leukemia By Next Generation Sequencing: Association with Established Prognostic Variables and MRC Risk Groups

EUTOS Score Predicts Long-Term Outcome in Chronic Myeloid Leukemia Patients Transitioning from Pre-Imatinib Era to Imatinib upon Availability

Achieving Complete Cytogenetic Response and BCR-ABL PCR IS <1% within 12 Moths Are Important Goals for Imatinib Therapy in Newly Diagnosed, TKI-Naive Chronic Myeloid Leukemia Accelated Phase Patients

The Transcription Factor IRF8 is a Key Transcription Factor for Basophil Development

Leukemic Stem Cell Quantification Is Of Prognostic Value In Newly Diagnosed Patients In Chronic Phase Chronic Myeloid Leukemia (CML-CP) Receiving Nilotinib Therapy: Results From The ENEST1st Stem Cell Substudy

Serum Tryptase Is a Strong Predictive Biomarker That Improves Prognostication in Ph+ Chronic Myeloid Leukemia.

Comparison of Sokal, Hasford and EUTOS Scores in Terms of Long-Term Treatment Outcome According to the Risks in Each Prognostic Model: A Single Center Data Analyzed in 255 Early Chronic Phase Chronic Myeloid Leukemia Patients Treated with Frontline Imatinib Mesylate.

Pomalidomide in Myelofibrosis with Cytopenia: First Results of the Mpnsg 01–09 Study (ClinicalTrials.gov Identifier: NCT00949364).

Chronic Myelogenous Leukemia in the Era of Tyrosine Kinase Inhibitors: Is Sokal Score Still a Valid Predictor of Prognosis?

Chronic Myeloid Leukemia Presenting with Isolated Thrombocythemia: A Case Revealing Its Stem Cell Biology

Pomalidomide Therapy for Myelofibrosis: Analysis of Results From Three Consecutive Clinical Trials

Trilineage Perturbation of Hematopoiesis In Neonates with Down Syndrome

Role of Focal Adhesion Kinase in Myelotoxicity, Inflammatory Stress Response and Myeloid Cell Functions.

Philadelphia Chromosome Positive Acute Myeloid Leukemia: An Aggressive Acute Leukemia with Clinicopathologic Features Distinct from Chronic Myeloid Leukemia in Blast Crisis.

Enumeration and Immunologic Characterization of Basophils in Normal Bone Marrow and Patients with Myeloproliferative Disorders.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only